Evolocumab

Brand names: Repatha · Active ingredient: Evolocumab

In short: REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events. As an

Forms & strengthsREPATHA injection is a clear to opalescent, colorless to pale yellow solution available as follows: 140 mg/mL solution in a prefilled single-dose pen 140 mg/mL solution in a prefilled single-dose SureClick® autoinjector 140 mg/mL solution in a prefilled …
LabelAmgen USA Inc.
Label updatedOct 23, 2026

What is Evolocumab used for?

REPATHA is indicated:

To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events.

As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:

adults with hypercholesterolemia.

adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).

adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).

Evolocumab dosage

In adults at increased risk for CV events or with hypercholesterolemia:

The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously .

If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen.

In adults and pediatric patients aged 10 years and older with HeFH:

The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously .

If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen.

In adults and pediatric patients aged 10 years and older with HoFH:

The initial recommended dosage of REPATHA is 420 mg once monthly administered subcutaneously .

The dosage can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks.

Patients on lipid apheresis may initiate treatment with 420 mg every 2 weeks to correspond with their apheresis schedule. Administer REPATHA after the apheresis session is complete.

Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be measured as early as 4 weeks after initiation.

When monitoring LDL-C for patients receiving REPATHA 420 mg once monthly, note that LDL-C can vary during the dosing interval in some patients; recommend measuring LDL-C just prior to the next scheduled dose .

If a dose is missed:

Within 7 days from the missed dose, instruct the patient to administer REPATHA and resume the patient's original schedule.

More than 7 days after the missed dose:

For an every 2-week dose, instruct the patient to wait until the next dose on the original schedule.

For a once-monthly dose, instruct the patient to administer the dose and start a new schedule based on this date.

REPATHA is available as prefilled single-dose SureClick® autoinjectors and prefilled single-dose syringes that either contain dry natural rubber (a derivative of latex) in the needle cover or are not made with natural rubber latex . Consider prescribing a presentation of REPATHA that does not contain dry natural rubber for individuals that are sensitive to latex .

Train patients and/or caregivers on how to prepare and administer REPATHA, according to the Instructions for Use and instruct them to read and follow the Instructions for Use each time they use REPATHA.

Prior to use, allow REPATHA to warm to room temperature for at least 30 minutes for the prefilled single-dose pen, prefilled single-dose SureClick® autoinjector, or prefilled single-dose syringe if REPATHA has been refrigerated .

Visually inspect REPATHA prior to administration. REPATHA is a clear to opalescent, colorless to pale yellow solution. …

How to take Evolocumab — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-Approved Patient Labeling (Patient Information and Instructions for Use).

Hypersensitivity

Inform patients that serious hypersensitivity reactions (e.g., angioedema) have been reported in patients treated with REPATHA. Advise patients on the symptoms of hypersensitivity reactions and instruct them to discontinue REPATHA and seek medical attention promptly, if such symptoms occur.

Latex-Sensitivity

Instruct patients to inform their healthcare provider if they are sensitive to latex. Inform patients that REPATHA is available as prefilled single-dose SureClick® autoinjectors and prefilled single-dose syringes that either contain dry natural rubber (a derivative of latex) in the needle cover or are not made with natural rubber latex, and the carton and Instructions for Use state if the product contains dry natural rubber. Advise latex-sensitive patients that the needle cover of the glass prefilled single-dose SureClick® autoinjector and prefilled single-dose syringe that contain dry natural rubber (a derivative of latex) may cause allergic reactions in individuals sensitive to latex . …

Warnings & precautions

Do not take this medicine if: REPATHA is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in REPATHA. Serious hypersensitivity reactions including angioedema have occurred in patients treated with REPATHA .

Hypersensitivity reactions, including angioedema, have been reported in patients treated with REPATHA. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with REPATHA, treat according to the standard of care, and monitor until signs and symptoms resolve. REPATHA is contraindicated in patients with a history of serious hypersensitivity reactions to evolocumab or any excipient in REPATHA .

The prefilled single-dose SureClick® autoinjector and prefilled single-dose syringe presentations of REPATHA that contain dry natural rubber (a derivative of latex) in the needle cover may cause an allergic reaction in individuals sensitive to latex. Instruct patients to inform their healthcare provider if they are sensitive to latex. Consider prescribing a presentation of REPATHA that does not contain dry natural rubber for individuals that are sensitive to latex .

Evolocumab side effects

The following adverse reactions are also discussed in other sections of the label:

Hypersensitivity Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions in Adults with Hypercholesterolemia

The data described below reflect exposure to REPATHA in 8 placebo-controlled trials that included 2,651 patients treated with REPATHA, including 557 exposed for 6 months and 515 exposed for 1 year (median treatment duration of 12 weeks). The mean age of the population was 57 years, 49% of the population were female, 85% White, 6% Black or African American, 8% Asian, and 2% other races.

Adverse Reactions in a 52-Week Controlled Trial

In a 52-week, double-blind, randomized, placebo-controlled trial, 599 patients received 420 mg of REPATHA subcutaneously once monthly . The mean age was 56 years (range: 22 to 75 years), 23% were older than 65 years, 52% female, 80% White, 8% Black or African American, 6% Asian; 6% identified as Hispanic or Latino ethnicity. Adverse reactions reported in at least 3% of REPATHA-treated patients, and more frequently than in placebo-treated patients are shown in Table 1. Adverse reactions led to discontinuation of treatment in 2.2% of REPATHA-treated patients and 1% of placebo-treated patients. …

About this medicine

Evolocumab is a human monoclonal immunoglobulin G2 (IgG2) directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). Evolocumab has an approximate molecular weight (MW) of 144 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.

REPATHA is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution for subcutaneous use. Each 1 mL prefilled single-dose pen, prefilled single-dose SureClick® autoinjector and prefilled single-dose syringe contains 140 mg evolocumab, acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in Water for Injection, USP. Sodium hydroxide may be used to adjust to a pH of 5.0.

How it works: Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cd61e902-166d-4aa6-9f3c-a18c1008d07e. Read the full official label on DailyMed.

Related medicines

Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone